CIDARA Aktie

 

The company earned an important fast-track review designation for a pipeline medication....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation...

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS)....

The company could have quite a winner on its hands with its most advanced pipeline drug....

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing....

Toronto (www.aktiencheck.de) - Cidara Therapeutics-Aktienanalyse von RBC Capital Markets: Brian Abrahams, Analyst von RBC Capital Markets, erhöhe das Kursziel für die Aktie von Cidara Therapeutics Inc. (ISIN: US1717572069, WKN: A3D4A6, Ticker-Symbol: 20D, NASDAQ-Symbol: CDTX) von 115 auf 137 USD angehoben und das "outperform"-Rating beibehalten. [mehr]...

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere...

Mit Cidara Therapeutics zaubert ein Dauerbrenner unserer sharedealsPlus-Community eine wahnsinnige Performance in die Depots: +793% innerhalb eines Jahres sprechen eine klare Sprache: Das Biotechunternehmen könnte den milliardenschweren Grippe-Markt gründlich umkrempeln. Mit der Cidara-Aktie haben SD-Mitglieder in den vergangenen Jahren immer wieder stattliche Trading-Renditen einfahren können. Doch nach den ersten Phase-2-Daten des Wirkstoffkandidaten CD388 im Oktober […] The post Cidara Therapeutics: sharedealsPlus-Tipp mit +793% in 11 Monaten first appeared on sharedeals.de....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

- Update based on FDA End-of- Phase 2 meeting outcome...

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation...

Davarpanah, Nicole Negar - Vorstand - Tag der Transaktion: 2025-09-11...

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences....

Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter...

Ra Capital Management, LLC - Aufsichtsrat - Tag der Transaktion: 2025-06-26...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes....